Tatsu’s Newsletter Podcast
Bloomberg: $35/month. Financial Times: $42/month. The Economist: $17/month. Original analysis by Tatsu with 40+ footnotes: $8/month, 14-day free trial. Share this preview with anyone still describing military neurotechnology as "therapeutic." "Biotechnology will become the new strategic commanding heights of national defense, from biomaterials to brain control weapons." Major General He Fuchu, then-President, China's Academy of Military Medical Sciences, 2015. COVID brought into public awareness what biosecurity researchers had been documenting for decades: bioweapons research is functionally unregulated globally. The 1972 Biological Weapons Convention has no inspectorate, no enforcement mechanism, and no verification protocol. There is no IAEA for biology. There is no equivalent of the nuclear safeguards regime that constrains fissile material. There is a category of research operating under even fewer constraints. It has been funded by the US Department of Defense for sixty years, in the same dual-use territory the BWC nominally regulates, with the medical-research justification gating the funding, the FDA fast-tracking the regulatory pathway, and the BWC's verification architecture unable to detect what is being built. The technology is neural and biological. The application is military. This piece documents how the system works, what it currently produces, where it is heading, and why the existing bioethics critique cannot stop it. In 2006, the University of Pennsylvania bioethicist Jonathan D. Moreno published Mind Wars: Brain Science and the Military, the foundational text on US military neuroscience.[1] In it, Moreno documented a pattern that had been visible to ethicists for decades but had no formal name: the systematic use of medical-research justifications (treating wounded service members, restoring function to amputees, mitigating traumatic brain injury) as the regulatory and political vehicle through which the Department of Defense funds dual-use research with primarily offensive military applications. Moreno called this dynamic a feature of the dual-use cycle. He did not give it a unifying name. In 2018, the King's College London biosecurity researcher Filippa Lentzos, NGO Coordinator for the Biological Weapons Convention, extended the analysis into the bioweapons domain.[2] Lentzos documented what she calls the governance deficit in modern engineering biology: the failure of the BWC's 1972 verification architecture to address dual-use platform technologies that produce medical outputs and bioweapon outputs from identical hardware. Her work, combined with the broader Dual-Use Research of Concern (DURC) literature and the contributions of Patrick Lin at Cal Poly and Nicholas Evans at U Mass Lowell, established what is now the standard ethical critique of US military biotech.[3] This piece names that dynamic as a system: Therapeutic Cover. The term consolidates what Moreno, Lentzos, Lin, and the broader bioethics community have documented over two decades. The contribution here is not the ethical observation, which is well-established. The contribution is the structural read. Therapeutic Cover is a military procurement pipeline, not a public-relations playbook. It is the budget line, the regulatory pathway, the FDA designation, the treaty exemption, and the political-coalition mechanism that makes the entire program fundable, deployable, and structurally permanent. A single vivid example, to anchor what we are talking about. On December 2, 2024, at the I/ITSEC defense simulation conference, the Charlottesville firm Luna Labs USA demonstrated its 3-Axis Wearable Adaptive Vestibular Stimulation system, branded 3WAVES, paired with an Aechelon Technology image generator inside an F-16 cockpit simulator.[4] The pilot trainee wore a Varjo XR-4 Secure Edition mixed-reality headset. As the simulator pitched and rolled in software, the 3WAVES system delivered synchronized galvanic vestibular stimulation directly to the inner ear, inducing artificial sensations of yaw, pitch, and roll. The public framing: reduces simulator-induced cybersickness. The actual capability: the Pentagon can now make a pilot's nervous system feel motion the cockpit is not producing. A remote drone operator in Las Vegas can be neurologically synchronized with a platform flying over the Persian Gulf. The therapeutic justification was simulator sickness. The capability produced is operational neural integration. Below the paywall, the full structural read: * The mechanism, in four parts: how Therapeutic Cover functions as budget, regulation, political consent, and treaty exemption. * The two convergent platforms it protects: programmable biology (DARPA Bio-MOD, Pharmacy on Demand, the May 2026 Biomolecule Purification RFI) and programmable nervous systems (NESD, N3, MOANA, and the commercial BCI ecosystem). * Luna Labs USA as the worked example: one company, $58 million in federal contracts, Patent 12336822 for flexible electrodes, the 3WAVES vestibular system, and Defense Health Agency hydrogel contracts spanning all four pathways. * The 61-year continuous line: from Project Pandora in 1965 through Allan Frey's RF auditory paper to today's $58 billion Military Health System budget. The technical objective has not changed. * The financial backbone: Pentagon FY2027 MHS budget structure, where the $4.5 billion in medical RDT&E sits, and how the cover is the procurement infrastructure. * The asymmetry: China articulates the offensive doctrine publicly under Major General He Fuchu's Brain Battlefield framework. The US conducts the same research silently under therapeutic justification. * The treaty gap: why Lentzos calls modern engineering biology effectively unverifiable, and what that means for the next decade of governance. * The cost: Moreno's Disenhancement Paradox in the BCI era, and the legal question of whether a soldier using a closed-loop neural interface is using a weapon or acting as part of one. Start a 14-day free trial. Full investigation below. $80/year if you stay, for structural analysis that reads the budget documents the press releases avoid. What Therapeutic Cover is, and how it works Therapeutic Cover is the system through which the United States military funds dual-use biotechnology and neurotechnology research using medical-research justifications, with the consequence that the same research follows different rules than it would if funded as weapons development. The operative word is rules. The cover is a set of structural facts about how the federal government processes biotech and neurotech investment, not a marketing strategy. The cover functions across four mechanisms, each independently load-bearing. Mechanism One: Budget appropriations. Pentagon biotech research can be funded through multiple appropriations categories, each with different oversight rules. The Defense Health Agency's $4.5 billion medical research, development, testing, and evaluation budget faces medical ethics review. The Army Research Office or Office of Naval Research weapons-development lines face arms-control review. The same neural-interface research program is fungible across these line items. The Pentagon routes it through DHA on purpose, because the resulting oversight environment is more permissive for dual-use platform technologies. The cover is the budget code. Mechanism Two: Regulatory pathway. FDA Breakthrough Device designation is a fast-track approval mechanism for medical devices that treat serious conditions and have no adequate alternative. Once a neural-interface device receives Breakthrough designation for a medical indication (Synchron's Stentrode for paralysis communication, Paradromics' Connexus for mind-reading, Precision Neuroscience's Layer 7 for cognitive monitoring), the safety profile transfers automatically to subsequent applications without a separate regulatory authorization. The cover is the FDA label. Mechanism Three: Political consent. US public opinion supports research that helps wounded service members, paralyzed patients, ALS sufferers, and TBI survivors. US public opinion is significantly more skeptical of research that integrates neural implants into healthy, able-bodied operators for combat purposes. Therapeutic Cover converts the first political capital into funding for the second. The medical use case is the vote-getter. The cover is the political coalition. Mechanism Four: Treaty compliance. The Biological Weapons Convention bans biotech development that has "no justification for prophylactic, protective, or other peaceful purposes." Medical research is by definition a peaceful purpose. DARPA's Bio-MOD freeze-dried protein-synthesis pellets that produce vaccines are BWC-compliant. The same pellets, loaded with a different genetic template, produce combat stimulants, performance-altering peptides, or population-specific toxins. The cover is the treaty exemption. The four mechanisms reinforce each other. The budget code enables the FDA pathway, which produces the safety profile, which secures the political coalition, which funds the budget code. The treaty exemption operates at the level of international law and prevents external pressure from breaking the loop. No single mechanism is the cover. The cover is the system. Reform proposals consistently address one mechanism at a time. The system is funded to outlive each of them. This is the structural read that Moreno's bioethical critique pointed at but did not name. It is what makes the cover impossible to dismantle via the standard reform pathways (clearer FDA rules, better congressional oversight, stronger BWC verification). Each reform would only address one mechanism, while the other three continue to operate. The system is over-determined. The two convergent platforms Therapeutic Cover protects The cover currently protects two parallel research programs. The first is programmable biology, oriented around portable, on-demand manufacturing of any protein or small molecule the operator selects via a genetic template. The second is programmable nervous systems, oriented around bidirectional reading and writing of human neural activity at increasing resolution and bandwidth. Both programs converge on the same operational endpoint: the warfighter as a programmable biological-digital platform. Programmable biology determines what flows into the body. Programmable nervous systems determine how the body integrates with external systems. The two together close the loop. Programmable biology, current status: DARPA's Battlefield Medicine program splits research between Pharmacy on Demand (PoD) for small-molecule chemical synthesis and Biologically-derived Medicines on Demand (Bio-MOD) for complex biologics.[5] On Demand Pharmaceuticals received a DARPA contract in September 2020 to develop field-deployable continuous-flow synthesis platforms with disclosed outputs including diphenhydramine, lidocaine, diazepam, fluoxetine, and atropine.[6] The atropine production capability is the giveaway: the platform is designed for hundreds to thousands of doses of nerve-agent countermeasure on demand, in theater, within hours.[7] The biologics side runs through the University of Maryland Baltimore County under Dr. Govind Rao, who pioneered Cell-Free Protein Synthesis (CFPS) for the Bio-MOD platform.[8] CFPS bypasses the need for living engineered cells in theater. Cell lysate machinery (ribosomes, transfer RNAs, polymerases) is harvested, supplemented with chaperone proteins, and freeze-dried into shelf-stable pellets. The pellets remain inert until rehydrated with local water, amino acids, energy substrates, and the genetic template for the target protein.[9] The companion program is Reimagining Protein Manufacturing (RPM), a 50-month DARPA initiative managed by Dr. Amy Jenkins, which optimizes production yield and post-translational modification control for high-purity biologics output.[10] CFPS yields now exceed grams of protein per liter of reaction volume. The technical bottleneck has been purification. DARPA's solution arrived in public form on May 15, 2026, with Request for Information DARPA-SN-26-66, titled "Biomolecule Purification," issued by the DARPA Microsystems Technology Office under Product Service Code AC12 and NAICS code 541715.[11] The RFI seeks single-step, tunable purification platforms capable of separating complex molecules from raw feedstock without affinity tags or conventional chromatography. When this solicitation closes and the technology matures, the entire pharmaceutical-industrial supply chain becomes optional for the US military. A soldier with pellets and a purification device can produce any protein the genetic template encodes. The dual-use disclosure is in DARPA's own documentation. Stated applications include "synthetic lubricants for drones, combat stimulants, or artificial toxins" alongside the medical use cases.[12] Therapeutic Cover does not require concealing the dual use. It requires routing the funding through medical justification, which the disclosure does not threaten because the medical justification is also true. Programmable nervous systems, current status: DARPA's neural-engineering portfolio runs through two flagship programs. The Neural Engineering System Design (NESD) program launched in January 2016 with up to $60 million in funding, specifying a million-neuron implantable interface capable of recording from and writing to at least one million individual neurons simultaneously.[13] NESD performers included Columbia University (non-penetrating CMOS over visual cortex), Brown University (networks of submillimeter neurograin sensors powered via external RF), and Paradromics.[14] The Next-Generation Nonsurgical Neurotechnology (N3) program, launched in 2018 under Dr. Al Emondi, mandated wearable neural interfaces capable of reading and writing to 16 independent channels within a 16-cubic-millimeter volume at sub-millimeter spatial resolution with latency under 50 milliseconds.[15] Rice University's MOANA (Magnetic, Optical, and Acoustic Neural Access) project, led by Dr. Jacob Robinson, received $18 million in 2019 and an $8 million follow-on in 2021. MOANA combines diffuse optical tomography with magnetogenetic stimulation via viral vectors delivering genes encoding magnetic-field-sensitive proteins.[16] The viral vector makes individual neurons addressable from outside the skull via external magnetic fields. No surgery required. The commercial BCI ecosystem is six companies, all federally connected: Company | Device | Federal pipe | Funding -------------+----------------+--------------------------+------------------ Synchron | Stentrode (16 | Navy contract | $75M Series B | electrodes, | N0018922F3040 through | (Bezos | endovascular) | 2028; early DARPA + ONR | Expeditions, | | | Gates Frontier) | | | [^17] Paradromics | Connexus (421 | DARPA NESD BAA 16-09, | Over $84M private | electrodes, | contract option of $18M | (Prime Movers | intracortical) | | Lab) [^18] Precision | Layer 7 (4,096 | Filings to NIST/Commerce | $155M total, Neuroscience | channels, | on BCI semiconductor | Series C led by | cortical | protection | General Equity | surface) | | [^19] Neuralink | N1 / Telepathy | Self-certified SBA | $647M Series D at | (1,024 | "small disadvantaged | $9B valuation | threads, | business," April 2025 | [^20] | intracortical) | | INBRAIN | Graphene | Strategic collaboration | Backed by CDTI Neuroelectronics | cortical | with Microsoft Azure for | Innvierte [^21] | interface | closed-loop neural | | | decoding | Blackrock | Utah Array / | Prime DARPA Biological | $200M from Tether Microsystems | Neuralace | Technologies Office | April 2024; $50M+ | | contracts | federal [^22] Every company in the table builds its commercial value on medical applications (paralysis communication, prosthetics, cognitive monitoring) while operating inside the DARPA-Pentagon funding ecosystem. The commercial layer is the distribution mechanism for Therapeutic Cover. The companies sell devices to hospitals and patients. The Pentagon harvests the resulting clinical safety data, FDA designations, and manufacturing capacity for military applications. The therapeutic frame is the supply chain. The contracting mechanisms that move money and intellectual property through this ecosystem are non-standard. DARPA uses Other Transaction Authorities (OTAs) for the venture-stage relationships with companies like Neuralink and Synchron, a contracting pathway that bypasses the Federal Acquisition Regulation's slower disclosure requirements. Broad Agency Announcements (BAAs) like the NESD 16-09 solicitation handle academic-and-industry research contracts. SBIR Phase II Topics, the mechanism Luna Labs uses for Defense Health Agency contracts like Brain SHIELD (DHA242-003), provide $1 to 2 million awards in 24-month cycles. Cooperative Research and Development Agreements (CRADAs) move IP and data between federal labs and private companies without direct funding. The combined effect is that the BCI commercial layer operates inside a contracting architecture specifically designed to move faster than traditional military procurement and to bypass much of the disclosure that traditional weapons-development contracts would trigger. The contracting infrastructure is itself part of the cover. Luna Labs USA: one company, all four pathways Luna Labs USA is the most instructive case study because the company operates across every pathway Therapeutic Cover protects, inside a single corporate structure. Spun out from publicly traded Luna Innovations in March 2022 through a management-led buyout, the firm is headquartered in Charlottesville, Virginia and has received over $58 million in federal funding across contracts and grants since spin-out.[23] The neural-interface hardware is protected under US Patent 12336822, "Methods of making flexible electrodes," granted to Luna Labs USA on June 24, 2025.[24] The patent describes implantable neural probes constructed from electrospun nanofiber mats that match the mechanical impedance of peripheral nerves and soft brain tissue. The probes minimize the foreign body response that has historically degraded chronic implants like the Utah Array. The patent explicitly targets sustained, high-fidelity, bidirectional communication over extended operational lifecycles. The clinical framing of the patent is regenerative medicine for amputees, paralyzed patients, and peripheral nerve injuries. The operational implication is that Luna Labs has solved the chronic implant problem that has dogged BCI hardware for two decades. Their electrodes can stay in nerve tissue for years without the immune response degrading the signal. The medical use case funded the research. The military use case inherits the solution. The vestibular side runs through the 3WAVES system, supported by an Air Force contract FA489024P0024 awarded under the May 2024 Super Goggles Challenge and subcontract 7127-DPA-2S-MAYO with Mayo Clinic Arizona in January 2025 for function-verification studies.[25] The 3WAVES F-16 simulator demonstration described in the opening is the productionized output of these contracts. The broader Luna Labs portfolio with the Defense Health Agency reads as a textbook Therapeutic Cover deployment: * Brain SHIELD (Topic DHA242-003): thermoresponsive hydrogel drug-delivery system for open traumatic brain injury. Medical justification. Dual-use payload mechanism. * TBI Liposomes (Topic DHA243-002): biopolymer-coated liposomal drug delivery for prolonged TBI treatment. Same. * BlastPredict (Topic DHA251-002): mobile application for predicting blast overpressure exposure and resulting cognitive deficits. The neurological data set this generates is the same data set that enables predictive modeling for offensive neural-targeting applications. * SMART3D (Topic DHA24C-001): 3D-printed synthetic self-healing soft tissues for trauma training. Once you can fabricate self-healing tissue analogs, you can also fabricate synthetic biological substrates for offensive bioresearch. * Contract HQ086025CE028 (Missile Defense Agency): lightweight lightning-strike coating for aerospace structures. * Contract W31P4Q22C0001 (DARPA SBIR Phase II): chemically resistant self-decontaminating CARC overcoat for passive battlefield defense.[26] The portfolio reads internally as a coherent military biotech and biomaterials development program. Read externally through Therapeutic Cover, it reads as fragmented medical and defense research. The two readings are not in tension. They are the same program from different vantage points. The cover is what allows both readings to be simultaneously true. Luna Labs files patents, applies for SBIR grants, hosts customer visits, and pays its taxes. Therapeutic Cover does not require any of those activities to be conspiratorial. It only requires them to be unread. The 61-year continuous line Therapeutic Cover did not begin with the 2024 Luna Labs demo or the 2016 NESD program. It has run continuously since 1965. In 1965, the Advanced Research Projects Agency launched Project Pandora under program manager Richard S. Cesaro inside the Walter Reed Army Institute of Research.[27] Pandora was the US response to the "Moscow Signal," sustained low-intensity microwave irradiation of the US embassy in Moscow by Soviet intelligence between 1953 and 1979 at frequencies between 2.5 and 4.0 gigahertz. Under a classified sub-program called BIZARRE, Johns Hopkins Applied Physics Laboratory researchers irradiated chimpanzees and rhesus monkeys in anechoic chambers to study behavior modification, heart rate, and chromosomal damage. By April 1969, the Project Pandora Science Advisory Committee was preparing a transition to unwitting human experimentation at Fort Detrick, with protective shielding for eyes and gonads, over a six-month exposure window.[28] The same year, Dr. Allan Frey at Willow Grove demonstrated that pulsed radio-frequency exposure at 1310 megahertz and 2982 megahertz could induce auditory sensations of buzzing, clicking, or knocking inside the human skull, without any technical receiver and at power densities well below the threshold for thermal tissue damage.[29] Frey had proved that the nervous system itself could function as a direct receiver for modulated electromagnetic inputs. The continuity from 1965 to 2026 is empirical, not metaphorical: funding-line continuous, institutionally continuous, and technically continuous. The Walter Reed Army Institute of Research, established as the host for Project Pandora, remains an active research site for the Defense Health Agency. The Johns Hopkins Applied Physics Laboratory remains a prime DARPA contractor. The Fort Detrick installation remains an active Army medical research command facility. The Air Force Research Laboratory and Office of Naval Research, both of which inherited portions of the Pandora research program, remain primary funding sources for the contemporary BCI commercial ecosystem. The technical objective has evolved from raw electromagnetic exposure to high-precision neural implants. The institutional infrastructure has not changed. The same buildings, the same contractors, the same funding lines, and a continuously updated set of medical justifications. The financial backbone: where the $58 billion is buried The Pentagon's proposed Military Health System (MHS) budget for fiscal year 2027 is $58 billion.[30] The proposed split allocates the larger share to the Private Sector Care Program and the smaller share to the Combat Operational and Medical Readiness account, with over $4.5 billion specifically for medical research, development, testing, and evaluation (RDT&E). Inside that $4.5 billion sit the neurotechnology contracts, cell-free bioproduction grants, cognitive diagnostic research, implantable-electrode patents, and vestibular stimulation studies. Inside that same budget sit the Defense Health Agency contracts to Luna Labs, the BCI ecosystem federal contracts, and the DARPA medical-program transitions. The Therapeutic Cover financial mechanism produces three structural advantages by housing this research inside MHS: Shielding from public scrutiny. Medical research budgets are politically protected. Service member care is one of the few line items where congressional and media oversight is bipartisan-defensive rather than oversight-aggressive. Expedited regulatory pathway. FDA Breakthrough Device designation and SBIR fast-track mechanisms are available to MHS-funded research that would not be available to weapons-development-funded research. DHA contracting authority. Defense Health Agency contracting mechanisms differ from Army Research Office or Office of Naval Research weapons contracts in disclosure requirements, ethical review structure, and Congressional reporting obligations. The cover is the procurement infrastructure because procurement infrastructure determines which research gets funded, which contracts get awarded, and which capabilities reach operational deployment. The $4.5 billion is the cover working, in dollar form, on a Congressional appropriations basis, every fiscal year. The asymmetry: China runs the same program transparently The United States is not unique in pursuing programmable biology and programmable nervous systems as military capability. China's program is comparable in scope and arguably more advanced in specific domains. What is unique to the United States is the use of Therapeutic Cover as the operating mechanism. China runs the same research program but does not require the cover. China's program operates under the doctrine of Military-Civil Fusion (MCF), centrally directed through the Central Military Commission's Science and Technology Commission and state MCF development funds.[31] The academic anchors are concentrated in Tsinghua University (National Engineering Laboratory for Neuromodulation; high-channel-count invasive BCI microchips), Zhejiang University (first successful human intracortical BCI implant in 2020; EEG-based drone swarm control), and Tianjin University (steady-state visual evoked potential decoding; non-invasive BCI integrated with augmented reality).[32] The doctrinal architecture has been articulated openly by senior Chinese military leadership. Lt. Gen. Liu Guozhi, Director of the CMC Science and Technology Commission, has declared that human-machine hybrid intelligence represents the highest form of future operational capability.[33] Major General He Fuchu, former president of the Academy of Military Medical Sciences and a leading architect of military-civil fusion in biotechnology, has predicted in published writings that the weaponization of living organisms will become an inevitable national security reality. He Fuchu's framework names two operational domains: * Biological Dominance (制生权): control over biological and genomic pathways via gene editing, synthetic pathogen design, and human enhancement. * Brain Battlefield (头脑战场): cognitive modeling, psychotropic pharmacology, and bidirectional BCIs to target sensory perceptions, emotional states, and decision-making capacities of enemy commanders and civilian populations.[34] The asymmetry is the point. China articulates the offensive doctrine publicly. The US conducts the same research silently through Therapeutic Cover. Both are working on the same technical objectives. Only one is honest about what those objectives are. The asymmetry exists because the political conditions are different. The Chinese Communist Party does not require a medical justification to fund weapons research. The US Congress, the US courts, the US press, and the US public do. Therapeutic Cover is the structure that lets the US program operate inside US political constraints while keeping pace with Chinese transparency. The cover is the only available pathway, given the operating environment. Major General He Fuchu publishes his offensive doctrine in academic English. DARPA publishes its parallel objectives in SAM.gov solicitations. One government is more embarrassed by the publication than the other. This is why the cover cannot be reformed away. Removing the cover would require either (a) abandoning the research, which would cede the field to China, or (b) US politics tolerating openly weaponized biotech and BCI research, which it currently does not. The treaty gap: why Lentzos says modern biology is unverifiable The Biological Weapons Convention is the international legal instrument that should constrain dual-use biotech research. Lentzos has documented why it does not.[35] Three structural problems: Definitions. The BWC's "general purpose criterion" relies on a binary distinction between peaceful and non-peaceful purposes. Modern dual-use platform technologies (Bio-MOD, RPM, cell-free biomanufacturing) are intrinsically dual-purpose by design. The same hardware, with a different genetic template input, produces different output. The BWC's definitional architecture cannot distinguish between the two states because the hardware is identical. Verification. Unlike the Chemical Weapons Convention, the BWC has no legally binding verification protocol and no independent inspectorate. Negotiations for a verification mechanism collapsed in 2001. The treaty relies on voluntary Confidence-Building Measures submitted by member states. The verification problem is now structurally unsolvable: cell-free lysates can be freeze-dried, transported in standard mail packaging, and rehydrated in any non-laboratory setting. Physical inspection of facilities cannot reveal capability that is distributed across pellets and templates rather than concentrated in stationary infrastructure. Genomic targeting. The proliferation of open-source genomic databases combined with machine-learning analysis introduces the theoretical possibility of population-specific genetic weapons. The ethnic diversity of the United States provides a protective buffer against the most highly targeted versions, but the unauthorized collection, sharing, and analysis of large-scale genomic data remains a national security threat that falls entirely outside current BWC regulatory scope.[36] Lentzos's framework reveals the deepest structural feature of Therapeutic Cover. The cover is internally consistent with the BWC because the BWC's verification architecture cannot see what the cover is doing. The treaty does not exempt the program. The treaty cannot detect the program. This is a different kind of legal permanence than "explicit treaty allowance." The cover persists because international law has no instrument capable of objecting to it. The cost: Moreno's Disenhancement Paradox in the BCI era The bioethical cost of Therapeutic Cover falls on the warfighter, not the system that designs the war. Moreno's central contribution to the literature is the Disenhancement Paradox, the observation that neural and pharmacological modifications that are highly adaptive in combat environments become profound clinical disenhancements in civilian society.[37] The mechanism is observable in the existing veteran population without any reference to advanced neurotechnology. Heightened threat perception, which improves combat survival, manifests as severe clinical paranoia in civilian settings. Suppression of pain, fatigue, and fear through pharmacological intervention disrupts natural sleep architecture and emotional baseline, leading to chronic post-traumatic stress and social reintegration failure. The BCI layer extends the paradox in a way previous warfighter pharmacology could not. As BCIs advance toward bidirectional, closed-loop systems that integrate machine-learning decoders with brain stimulation, individual human agency erodes. If a reactive BCI translates a soldier's preconscious neural response into an automated command to fire, the traditional legal framework of individual responsibility under International Humanitarian Law is compromised.[38] The operator becomes a biological processing component of a broader semi-autonomous weapon system. The legal question of whether the operator is using the weapon or is acting as part of the weapon becomes unanswerable, and the unanswerability is the point. Accountability dissolves into the closed loop. The Luna Labs 3WAVES system that synchronizes an operator's inner ear to a virtual cockpit does not have an off-switch for the conditioned responses it produces. The MOANA magnetogenetic stimulation that addresses individual neurons via external magnetic fields does not reverse the viral-vector gene insertion that made those neurons addressable in the first place. The veteran who comes home from a future BCI-integrated tour has been physically altered at the cellular level by the equipment that made him operationally effective. No legal or medical framework currently exists for that scenario. The complication compounds. Closed-loop BCIs are not commodities. They are proprietary corporate platforms. Synchron's Stentrode runs Synchron firmware. Neuralink's N1 runs Neuralink software. Paradromics' Connexus connects through Paradromics' decoder stack. Each is a closed system maintained by a private company on a corporate release schedule that has no obligation to the veteran whose nervous system the implant is integrated with. A veteran returning to civilian life with a closed-loop neural implant funded by the Defense Health Agency inherits the entire firmware lifecycle as a permanent dependency. If Synchron pivots its product line, the veteran's existing implant is either retrofit-compatible, deprecated, or unsupported. If Neuralink updates the N1 firmware in 2032, the veteran who received the implant in 2028 may find their decoder no longer integrates with the updated stack. If a BCI vendor goes bankrupt, the implant in the veteran's head becomes intellectual property attached to a creditor's lien in the bankruptcy estate. The Department of Veterans Affairs has no legal authority to compel a private company to maintain a discontinued product line, and the FDA's regulatory framework does not require post-market support for devices whose manufacturers have exited the category. This is the platform-veteran problem. The Pentagon funds the operational implant through Therapeutic Cover. The corporate vendor owns the firmware. The veteran lives with the hardware. The Defense Health Agency is the buyer; the soldier is the substrate; the company is the landlord. None of those three parties has unilateral legal authority to keep the implant operational independent of the others, and no existing legal framework defines what happens when their interests diverge. The veteran's neurological function becomes a subscription product with a termination clause that neither the veteran nor the VA controls. This is the moral mathematics of Therapeutic Cover. The medical justification that secures the funding cannot reverse the operational alteration that the funding produces. The cover does not transfer the cost to the system. It transfers the cost to the operator. Closing: the cover is the product Therapeutic Cover is what Moreno, Lentzos, and the broader bioethics community have been documenting for two decades. The contribution of this piece is to name it as a system and to read it as structural infrastructure rather than as ethical concern. The system is: * Sixty-one years old, running continuously from Project Pandora at Walter Reed in 1965 through Allan Frey's RF auditory work in the same year to today's Luna Labs vestibular and BCI platforms. * Funded at $4.5 billion per year minimum through the Defense Health Agency medical RDT&E budget, inside a $58 billion Military Health System appropriation. * Distributed across six commercial BCI companies and dozens of biotech contractors, with consistent federal pipes through DARPA, ONR, AFRL, DHA, and SBA mechanisms. * Productionized in single corporate units like Luna Labs USA, where one $58 million federal contract portfolio spans peripheral nerve electrodes, vestibular hacking, TBI hydrogels, and synthetic tissue 3D printing in one operating structure. * Asymmetric to the Chinese model, which runs the same research transparently under explicit offensive doctrine. The US program runs silently under medical justification because the US political environment does not tolerate transparency. * Outside the reach of the Biological Weapons Convention, whose 1972 verification architecture cannot detect dual-use platform technologies that operate from identical hardware. * Transferring the moral cost to the warfighter, whose neural and biological alterations from BCI-integrated operations do not reverse upon return to civilian life. Therapeutic Cover is not a public-relations strategy hiding a military program. The medical applications are real. The wounded soldiers are helped, the paralyzed patients do communicate, the simulator sickness does decrease. The cover works precisely because the medical application is true. The military application is the structural inheritance that comes free, included with the medical product, by virtue of how dual-use platform technologies work. The cover is the product. The Foundation for Defense of Democracies has not commented on Luna Labs' Patent 12336822. The Heritage Foundation has not analyzed DARPA-SN-26-66. The Brookings Institution has not addressed the Disenhancement Paradox in its Military Health System budget commentary. The institutions whose function is to read this kind of document are not reading it. The institutions whose function is to fund this kind of work are not advertising it. The space in between is where the program lives, and it has lived there for sixty-one years and counting. Part 2, paid only: Nothing Fixes This. Here's What Helps. The Biological Weapons Convention cannot be repaired. The 2001 verification protocol collapsed and is structurally impossible to revive in the current great-power environment. Part 2 walks through what realistic interventions remain below the treaty level: US domestic structural reform, small-coalition verification regimes among democracies, corporate liability frameworks, whistleblower protection infrastructure, and the technical surveillance mechanisms that could in principle detect offensive dual-use research. None of them stops the core Pentagon program. All of them constrain it at the margins. The honest reform stack is small, partial, and politically difficult. It is also all that is available. Part 2 explains why, and which interventions are actually worth pursuing. 14-day free trial. Cancel anytime. $80/year if you stay, or $8/month. Programmable biology, programmable nervous systems, $58 billion in medical research budget cover, sixty-one years of continuous funding. The space between the press releases and the patent office is where the program lives. Notes [1] Jonathan D. Moreno. Mind Wars: Brain Science and the Military. Dana Press, 2006. "On the Enhancement of Soldiers, Disenhancement, and the Importance of Context." [https://www.tandfonline.com/doi/full/10.1080/15027570.2025.2487329] Taylor & Francis, 2025. Foundational text and updated analysis on military neuroscience under dual-use justification. [2] "Biotechnologies and the Treaty Gap: Why Biological Weapons Governance Is Falling Behind." [https://inss.ndu.edu/Media/News/Article/4363698/biotechnologies-and-the-treaty-gap-why-biological-weapons-governance-is-falling/] Institute for National Strategic Studies. Dr. Filippa Lentzos analysis of BWC governance deficit. Also see "Dr Filippa Lentzos profile." [https://www.kcl.ac.uk/people/filippa-lentzos] King's College London. [3] "The Limits of Dual Use." [https://issues.org/the-limits-of-dual-use/] Issues in Science and Technology. Survey of the DURC literature including Patrick Lin (Cal Poly) and Nicholas Evans (U Mass Lowell) on dual-use bioethics. [4] "Aechelon Unveils First-of-its-kind Image Generator Interface for Luna Labs' 3WAVES." [https://aechelon.com/press-releases/lunalabs-vestibular-stimulator/] Aechelon Technology press release, December 2, 2024. Demonstration at I/ITSEC conference of 3WAVES paired with F-16 cockpit simulator and Varjo XR-4 Secure Edition headset. [5] "Battlefield Medicine." [https://www.darpa.mil/research/programs/battlefield-medicine] DARPA program page. Official description of Pharmacy on Demand (PoD) and Bio-MOD thrusts. [6] "DOD Pours Millions of Dollars into Print-on-Demand Drugs." [https://www.defenseone.com/technology/2020/09/dod-pours-millions-dollars-print-demand-drugs/168843/] Defense One, September 2020. DARPA contract to On Demand Pharmaceuticals. [7] "Battlefield medicine: disrupting (bio) pharmaceutical production." [https://www.openaccessjournals.com/articles/battlefield-medicine-disrupting-bio-pharmaceutical-production.pdf] Open Access Journals. Continuous flow manufacturing outputs including atropine. [8] "Making Medicine Mobile." [https://umbc.edu/stories/making-medicine-mobile/] University of Maryland Baltimore County. UMBC CAST led by Dr. Govind Rao under Bio-MOD grant. [9] "Cell-free systems for accelerating glycoprotein expression and biomanufacturing." [https://pmc.ncbi.nlm.nih.gov/articles/PMC7578589/] NIH PubMed Central. Cell-Free Protein Synthesis (CFPS) yields and freeze-dried pellet activation. [10] "Delivering Next-Gen Biomanufacturing Capability." [https://www.darpa.mil/news/2021/next-gen-biomanufacturing] DARPA news release. Reimagining Protein Manufacturing (RPM) program under Dr. Amy Jenkins. [11] "Request for Information: Biomolecule Purification." [https://sam.gov/opp/e69e8e0fd537432f81d23cf4d38faee5/view] SAM.gov listing, DARPA-SN-26-66, published May 15, 2026, DARPA Microsystems Technology Office. [12] "DTRA Works to Create Freeze-Dried Portable Biomanufacturing for Nimble Response to Emerging Biothreats." [https://globalbiodefense.com/2021/09/30/dtra-works-to-create-freeze-dried-portable-biomanufacturing-for-nimble-response-to-emerging-biothreats/] Global Biodefense. Dual-use applications including combat stimulants and synthetic toxins. [13] "Towards a High-Resolution, Implantable Neural Interface." [https://www.darpa.mil/news/2017/mplantable-neural-interface] DARPA news release. NESD program, up to $60 million, million-neuron interface specification. [14] "DARPA awards contracts to develop implantable neural interface." [https://militaryembedded.com/radar-ew/sensors/darpa-awards-contracts-to-develop-implantable-neural-interface] Military Embedded Systems. NESD contract awards to Columbia, Brown, and Paradromics. [15] "Six Paths to the Nonsurgical Future of Brain-Machine Interfaces." [https://www.darpa.mil/news/2019/nonsurgical-brain-machine-interfaces] DARPA news release. N3 program under Dr. Al Emondi with 16-channel, 16-cubic-millimeter, 50-millisecond latency specifications. [16] "Magnetism Plays Key Roles in DARPA Research to Develop Brain-Machine Interface without Surgery." [https://magneticsmag.com/magnetism-plays-key-roles-in-darpa-research-to-develop-brain-machine-interface-without-surgery/] Magnetics Magazine. Rice University MOANA under Dr. Jacob Robinson, $18M initial 2019 plus $8M 2021 follow-on. [17] "CONTRACT to SYNCHRON, LLC." [https://www.usaspending.gov/award/CONT_AWD_N0018922F3040_9700_N0017819D8609_9700] USA Spending. Navy contract N0018922F3040 through January 2028. Series B funding from Bezos Expeditions and Gates Frontier. [18] "Paradromics is Developing a Neural Interface System for the Navy." [https://www.afcea.org/signal-media/contracting/paradromics-developing-neural-interface-system-navy] AFCEA International. Paradromics DARPA NESD funding and venture history. [19] "Precision Neuroscience filing to NIST/Commerce." [https://downloads.regulations.gov/NIST-2022-0002-0079/attachment_1.pdf] Regulations.gov, December 12, 2022. Precision Neuroscience advocacy for BCI in US semiconductor protection. [20] "Elon Musk's Neuralink called itself a 'small disadvantaged business.' Then it was worth $9 billion." [https://qz.com/neuralink-elon-musk-small-disadvantaged-business] Quartz. Neuralink SBA self-certification April 2025. [21] "INBRAIN Neuroelectronics announces a collaboration with Microsoft to advance artificial intelligence in precision neurology." [https://www.pcb.ub.edu/en/inbrain-neuroelectronics-announces-a-collaboration-with-microsoft-to-advance-artificial-intelligence-in-precision-neurology/] Parc Científic de Barcelona. INBRAIN Microsoft Azure integration. [22] "Blackrock Microsystems." [https://www.highergov.com/awardee/blackrock-microsystems-inc-10015828/] HigherGov contract database. Federal contracts and Tether April 2024 investment. [23] "Luna Labs USA, LLC." [https://www.highergov.com/awardee/luna-labs-usa-llc-12872493/] HigherGov contract database. Over $58 million in federal funding since March 2022 spin-out. [24] "Patents Assigned to LUNA LABS USA, LLC." [https://patents.justia.com/assignee/luna-labs-usa-llc] Justia Patents Search. US Patent 12336822, "Methods of making flexible electrodes," June 24, 2025. [25] "3Waves Super Goggle Challenge Award." [https://sam.gov/workspace/contract/opp/5ae3c6b9bd2e40e58c52e3efb3e4da80/view] SAM.gov contract FA489024P0024. Mayo Clinic Arizona subcontract 7127-DPA-2S-MAYO via NAVAIR prime. [26] "Luna Labs USA, LLC Firm Profile." [https://www.sbir.gov/portfolio/2108241] SBIR portfolio listing of Luna Labs Defense Health Agency contracts (DHA242-003 Brain SHIELD, DHA243-002 TBI Liposomes, DHA251-002 BlastPredict, DHA24C-001 SMART3D), Missile Defense Agency contract HQ086025CE028, and DARPA SBIR Phase II W31P4Q22C0001. [27] "The Moscow Signals Declassified Microwave Mysteries: Projects PANDORA and BIZARRE." [https://nsarchive.gwu.edu/briefing-book/intelligence-russia-programs/2022-09-13/moscow-signals-declassified-microwave] National Security Archive, George Washington University. [28] "HEIN ONLINE Declassified Documents on Project Pandora." [https://nsarchive.gwu.edu/sites/default/files/documents/rhwvuj-tzy4b/15.pdf] National Security Archive. April 1969 Project Pandora Science Advisory Committee summaries. [29] "The early mind wars." [https://scispace.com/pdf/the-early-mind-wars-zjj6qc7vyx.pdf] Academic review of Dr. Allan Frey's 1965 research at Willow Grove. [30] "Defense Department proposes splitting military health system budget." [https://www.militarytimes.com/pay-benefits/military-benefits/health-care/2026/05/05/defense-department-proposes-splitting-military-health-system-budget/] Military Times, May 5, 2026. Pentagon proposed MHS FY2027 budget of $58 billion. [31] "Pulling Back the Curtain on China's Military-Civil Fusion." [https://cset.georgetown.edu/wp-content/uploads/CSET-Pulling-Back-the-Curtain-on-Chinas-Military-Civil-Fusion.pdf] Center for Security and Emerging Technology, Georgetown University. [32] "China AI-Brain Research." [https://cset.georgetown.edu/wp-content/uploads/CSET-China-AI-Brain-Research.pdf] Center for Security and Emerging Technology. Tsinghua, Zhejiang, and Tianjin BCI programs. [33] "Minds at War: China's Pursuit of Military Advantage through Cognitive Science and Biotechnology." [https://ndupress.ndu.edu/Portals/68/Documents/prism/prism_8-3/prism_8-3_Kania_82-101.pdf] National Defense University Press. Lt. Gen. Liu Guozhi and PLA doctrinal analysis. [34] "The Path to China's Intelligentized Warfare: Converging on the Metaverse Battlefield." [https://cyberdefensereview.army.mil/Portals/6/Documents/2024-Fall/Baughman_CDRV9N3-Fall-2024.pdf] Army Cyber Defense Review, Fall 2024. Major General He Fuchu's Biological Dominance and Brain Battlefield framework. [35] "Compliance and Enforcement in the Biological Weapons Regime." [https://unidir.org/files/2020-02/compliance-bio-weapons.pdf] UNIDIR. BWC verification architecture analysis. [36] "Scientific Risk Assessment of Genetic Weapon Systems." [https://nonproliferation.org/wp-content/uploads/2021/09/scientific_risk_assessment_genetic_weapon_systems06_cover.pdf] James Martin Center for Nonproliferation Studies. Population-specific genetic weapon vulnerability analysis. [37] "Mind Wars: Brain Science and the Military." [https://www.researchgate.net/publication/262534964_Mind_wars_Brain_science_and_the_military] Jonathan D. Moreno, ResearchGate review. Original 2006 articulation of the Disenhancement Paradox. [38] "Warfare at the speed of thought: can brain-computer interfaces comply with IHL?" [https://blogs.icrc.org/law-and-policy/2025/08/21/warfare-at-the-speed-of-thought-can-brain-computer-interfaces-comply-with-ihl/] International Committee of the Red Cross Law and Policy blog, August 21, 2025. BCI compliance with International Humanitarian Law. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit tatsuikeda.substack.com/subscribe [https://tatsuikeda.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_2]
153 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Tatsu’s Newsletter Podcast!